Help patients say yes to more moments

With AJOVY, patients may experience significantly
more migraine-free days vs placebo1

In chronic migraine, a reduction in monthly headache days of at least moderate severity was demonstrated during the 12-week period (primary endpoint), with results seen as early as week 11,2
Chronic Migraine
REDUCTION IN MONTHLY HEADACHE DAYS OF AT LEAST MODERATE SEVERITY (PRIMARY ENDPOINT)1,2
Line chart describing clinical trial data of chronic migraine patients receiving AJOVY over the 12-week period

Patients with a mean baseline of 12.8 headache days of at least moderate severity per month experienced1:

4.6 fewer headache days per month, on average, with monthly dosing (vs 2.5 days with placebo)1*

Patients with a mean baseline of 13.2 headache days of at least moderate severity per month experienced1:

4.3 fewer headache days per month, on average, with quarterly dosing (vs 2.5 days with placebo)1*

 *P<0.001.1

In episodic migraine, a reduction in monthly migraine days was demonstrated during the 12-week period (primary endpoint), with results seen as early as week 11,2
Episodic Migraine
REDUCTION IN MONTHLY MIGRAINE DAYS (PRIMARY ENDPOINT)1,2
Line chart describing clinical trial data of episodic migraine patients receiving AJOVY over the 12-week period

Patients with a mean baseline of 8.9 migraine days per month experienced1:


3.7 fewer migraine days per month, on average, with monthly dosing (vs 2.2 days with placebo)1†

Patients with a mean baseline of 9.2 migraine days per month experienced1:

3.4 fewer migraine days per month, on average, with quarterly dosing (vs 2.2 days with placebo)1†

 †P<0.001.1

Patients with chronic and episodic migraine receiving AJOVY had a significant reduction in the use of acute medication vs placebo (secondary endpoint)1,2‡

 

‡ Reduction of acute medication use (secondary endpoint): Patients in the chronic migraine trial with a mean baseline of 13.1 days for both monthly and quarterly dosing and 13.0 days for placebo saw a mean reduction of: 4.2 days for monthly dosing, 3.7 days for quarterly dosing vs 1.9 days with placebo, P<0.001. Patients in the episodic migraine trial with a mean baseline of 7.7 days for monthly dosing, 7.8 days for quarterly dosing, and 7.7 days for placebo saw a mean reduction of: 3.0 days for monthly dosing, 2.9 days for quarterly dosing vs 1.6 days with placebo, P<0.001.1,2

See clinical trial designs

AJOVY may help reduce migraine days by 50% or more1

Chronic Migraine

PATIENTS ACHIEVING AT LEAST A 50% REDUCTION IN MONTHLY AVERAGE HEADACHE DAYS OF AT LEAST MODERATE SEVERITY (SECONDARY ENDPOINT)1

Bar chart describing clinical trial data of chronic migraine patients receiving AJOVY with monthly dosing

37.6% of patients with chronic migraine achieved at least a 50% reduction in monthly average headache days with quarterly dosing vs 18.1% for placebo1*

*P<0.001.1

1 in 5 patients with chronic migraine experienced a 75% reduction in monthly average headache days vs 1 in 10 with placebo (post hoc analysis)2†

Episodic Migraine
PATIENTS ACHIEVING AT LEAST A 50% REDUCTION IN MONTHLY AVERAGE MIGRAINE DAYS (SECONDARY ENDPOINT)1
Episodic Chart

44.4% of patients with episodic migraine achieved at least a 50% reduction in monthly average migraine days with quarterly dosing vs 27.9% for placebo1‡

‡P<0.001.1

1 in 4 patients with episodic migraine experienced a 75% reduction in monthly average migraine days vs ~1 in 7 with placebo (post hoc analysis)2†

 

†For all post hoc analyses, no determination of statistical significance can be made and no conclusions should be drawn.

See clinical trial designs

Suggestions to explore next

Contine to AJOVY Dosing Flexibility page

Flexibility to help you meet your patients' needs1

 Dosing Options for AJOVY
Continue to Clinical trials design for AJOVY page

AJOVY was studied in two phase 3 clinical trials1

 See Clinical trial designs

Savings Offer for AJOVY

 DOWNLOAD SAVINGS OFFER